CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Optogenerapy is developing a novel drug delivery system for Multiple Sclerosis treatment using a bio-electronic implant. This system allows for controlled release of interferon-ß, minimizing side effects and improving patient adherence through subcutaneous delivery.
Optogenerapy proposes a new interferon-ß (IFN-ß) drug delivery system to revolutionize Multiple Sclerosis treatment.The aim is to develop and validate a new bio-electronic cell based implant device to be implanted subcutaneously providing controlled drug release during at least 6 months.
The cell confinement within a chamber sealed by a porous membrane allows the device to be easily implanted or removed.
At the same time, this membrane acts to prevent immune rejection and offers long-term safety…
FUNDACIO EURECAT
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Switzerland, Zuerich
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Ireland, Galway
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Spain, MADRID
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Poland, Lodz
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
